XML 19 R9.htm IDEA: XBRL DOCUMENT
v3.23.1

DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS | 3 Months Ended
--- | ---
Mar. 31, 2023
Acquisitions, Divestitures and Other Arrangements [Abstract] |
DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS | DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS Divestitures The following table summarizes the financial impact of divestitures including royalties, which are included in Other (income)/expense, net. Revenue and pretax earnings related to all divestitures were not material in all periods presented (excluding divestiture gains or losses).
| Three Months Ended March 31,
| Net Proceeds |  | Divestiture (Gains)/Losses |  | Royalty Income
Dollars in millions | 2023 |  | 2022 |  | 2023 |  | 2022 |  | 2023 |  | 2022
Diabetes business (a) | $ | 216 |  |  | $ | 172 |  |  | $ | — |  |  | $ | — |  |  | $ | (188) |  |  | $ | (170) |
Mature products and other | 4 |  |  | 225 |  |  | — |  |  | (211) |  |  | — |  |  | (1) |
Total | $ | 220 |  |  | $ | 397 |  |  | $ | — |  |  | $ | (211) |  |  | $ | (188) |  |  | $ | (171) |
(a) Net proceeds for diabetes business relates to net proceeds from royalties received subsequent to the sale of the diabetes business. Mature Products and Other During the first quarter of 2022, product rights to several mature products were sold to Cheplapharm, resulting in cash proceeds of $221 million and a divestiture gain of $211 million. Licensing and Other Arrangements The following table summarizes the financial impact of Keytruda* royalties, Tecentriq* royalties, upfront licensing fees and milestones for products that have not obtained commercial approval, which are included in Other (income)/expense, net.
| Three Months Ended March 31, |  |
Dollars in millions | 2023 |  | 2022 |  |  |  |
Keytruda* royalties | $ | (279) |  |  | $ | (221) |  |  |  |  |
Tecentriq* royalties | (30) |  |  | (25) |  |  |  |  |
Contingent milestone income | (31) |  |  | (41) |  |  |  |  |
Amortization of deferred income | (12) |  |  | (12) |  |  |  |  |
Other royalties and licensing income | (11) |  |  | (7) |  |  |  |  |
Total | $ | (363) |  |  | $ | (306) |  |  |  |  |
Immatics During the first quarter of 2022, BMS obtained a global exclusive license to Immatics' TCR bispecific IMA401 program. which is being studied in oncology. The trial commenced in May 2022. BMS and Immatics collaborate on the development and BMS will be responsible for the commercialization of IMA401 worldwide, including strategic decisions, regulatory responsibilities, funding and manufacturing. Immatics has the option to co-fund U.S. development in exchange for enhanced U.S. royalty payments and/or to co-promote IMA401 in the U.S. The transaction included an upfront payment of $150 million which was expensed to Acquired IPRD in the first quarter of 2022. Immatics is eligible to receive contingent development, regulatory and sales-based milestones of up to $770 million as well as royalties on global net sales. Dragonfly During the first quarter of 2022, a Phase I development milestone for interleukin-12 ("IL-12") was achieved resulting in a $175 million payment to Dragonfly and an Acquired IPRD charge. The parties also amended the terms of three future milestones by requiring the achievement of certain criteria by specified dates unless BMS notifies Dragonfly that it will discontinue development of IL-12. During the first quarter of 2023, BMS notified Dragonfly that it was terminating the global exclusive license that relates to Dragonfly’s IL-12. All rights to IL-12 were reverted back to Dragonfly effective April 18, 2023. Other Nimbus Change of Control Income During the first quarter of 2022, BMS and Nimbus Therapeutics entered into a settlement resolving all legal claims and business interests pertaining to Nimbus' TYK2 inhibitor resulting in $40 million of income included in Other (income)/expense. The settlement also provides for BMS to receive additional amounts for contingent development, regulatory approval and sales-based milestones and 10% of any change in control proceeds received by Nimbus Therapeutics related to its TYK2 inhibitor. In February 2023, Takeda acquired 100% ownership of Nimbus Therapeutics' TYK2 inhibitor for approximately $4.0 billion in upfront proceeds plus contingent sales-based milestones aggregating up to $2.0 billion. As a result, $400 million of income related to the change of control provision is included in Other (income)/expense during the first quarter of 2023 and is expected to be received in the second quarter of 2023.

X
- Definition Acquisitions, Divestitures and Other Arrangements [Abstract] + References No definition available. + Details
Name: | bmy_AcquisitionsDivestituresandOtherArrangementsAbstract
Namespace Prefix: | bmy_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -URI https://asc.fasb.org/subtopic&trid=2122178 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -URI https://asc.fasb.org/topic&trid=2303972 + Details
Name: | us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration